Cargando…
Nrf2与铁死亡在肿瘤耐药中的研究进展
Lung cancer is one of the most common cancers in the world, and its treatment strategy is mainly surgery combined with radiotherapy and chemotherapy. However, long-term chemotherapy will result in drug resistance, which is also one of the difficulties in the treatment of lung cancer. Ferroptosis is...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial board of Chinese Journal of Lung Cancer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663776/ https://www.ncbi.nlm.nih.gov/pubmed/37989339 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.31 |
_version_ | 1785138474137944064 |
---|---|
author | HU, Shuning ZOU, Xinru FANG, Yixuan LIU, Chengrui CHEN, Rui JI, Lili |
author_facet | HU, Shuning ZOU, Xinru FANG, Yixuan LIU, Chengrui CHEN, Rui JI, Lili |
author_sort | HU, Shuning |
collection | PubMed |
description | Lung cancer is one of the most common cancers in the world, and its treatment strategy is mainly surgery combined with radiotherapy and chemotherapy. However, long-term chemotherapy will result in drug resistance, which is also one of the difficulties in the treatment of lung cancer. Ferroptosis is an iron-dependent and lipid peroxidation-driven non-apoptotic cell death cascade, occurring when there is an imbalance of redox homeostasis in the cell. Nuclear factor erythroid 2-related factor 2 (Nrf2) is key for cellular antioxidant responses. Numerous studies suggest that Nrf2 assumes an extremely important role in regulation of ferroptosis, for its various functions in iron, lipid, and amino acid metabolism, and so on. In this review, a brief overview of the research progress of ferroptosis over the past decade will be presented. In particular, the mechanism of ferroptosis and the regulation of ferroptosis by Nrf2 will be discussed, as well as the role of the Nrf2 pathway and ferroptosis in tumor drug resistance, which will provide new research directions for the treatment of drug-resistant lung cancer patients. |
format | Online Article Text |
id | pubmed-10663776 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Editorial board of Chinese Journal of Lung Cancer |
record_format | MEDLINE/PubMed |
spelling | pubmed-106637762023-10-20 Nrf2与铁死亡在肿瘤耐药中的研究进展 HU, Shuning ZOU, Xinru FANG, Yixuan LIU, Chengrui CHEN, Rui JI, Lili Zhongguo Fei Ai Za Zhi Review Lung cancer is one of the most common cancers in the world, and its treatment strategy is mainly surgery combined with radiotherapy and chemotherapy. However, long-term chemotherapy will result in drug resistance, which is also one of the difficulties in the treatment of lung cancer. Ferroptosis is an iron-dependent and lipid peroxidation-driven non-apoptotic cell death cascade, occurring when there is an imbalance of redox homeostasis in the cell. Nuclear factor erythroid 2-related factor 2 (Nrf2) is key for cellular antioxidant responses. Numerous studies suggest that Nrf2 assumes an extremely important role in regulation of ferroptosis, for its various functions in iron, lipid, and amino acid metabolism, and so on. In this review, a brief overview of the research progress of ferroptosis over the past decade will be presented. In particular, the mechanism of ferroptosis and the regulation of ferroptosis by Nrf2 will be discussed, as well as the role of the Nrf2 pathway and ferroptosis in tumor drug resistance, which will provide new research directions for the treatment of drug-resistant lung cancer patients. Editorial board of Chinese Journal of Lung Cancer 2023-10-20 /pmc/articles/PMC10663776/ /pubmed/37989339 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.31 Text en 版权所有 © 2023《中国肺癌杂志》编辑部 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | Review HU, Shuning ZOU, Xinru FANG, Yixuan LIU, Chengrui CHEN, Rui JI, Lili Nrf2与铁死亡在肿瘤耐药中的研究进展 |
title | Nrf2与铁死亡在肿瘤耐药中的研究进展 |
title_full | Nrf2与铁死亡在肿瘤耐药中的研究进展 |
title_fullStr | Nrf2与铁死亡在肿瘤耐药中的研究进展 |
title_full_unstemmed | Nrf2与铁死亡在肿瘤耐药中的研究进展 |
title_short | Nrf2与铁死亡在肿瘤耐药中的研究进展 |
title_sort | nrf2与铁死亡在肿瘤耐药中的研究进展 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663776/ https://www.ncbi.nlm.nih.gov/pubmed/37989339 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.31 |
work_keys_str_mv | AT hushuning nrf2yǔtiěsǐwángzàizhǒngliúnàiyàozhōngdeyánjiūjìnzhǎn AT zouxinru nrf2yǔtiěsǐwángzàizhǒngliúnàiyàozhōngdeyánjiūjìnzhǎn AT fangyixuan nrf2yǔtiěsǐwángzàizhǒngliúnàiyàozhōngdeyánjiūjìnzhǎn AT liuchengrui nrf2yǔtiěsǐwángzàizhǒngliúnàiyàozhōngdeyánjiūjìnzhǎn AT chenrui nrf2yǔtiěsǐwángzàizhǒngliúnàiyàozhōngdeyánjiūjìnzhǎn AT jilili nrf2yǔtiěsǐwángzàizhǒngliúnàiyàozhōngdeyánjiūjìnzhǎn |